RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ocular Therapeutix Stock

Ocular Therapeutix P/E 2024

Ocular Therapeutix P/E

-2.35

Ticker

OCUL

ISIN

US67576A1007

WKN

A1180P

As of Nov 1, 2024, Ocular Therapeutix's P/E ratio was -2.35, a -62.99% change from the -6.35 P/E ratio recorded in the previous year.

The Ocular Therapeutix P/E history

Ocular Therapeutix Aktienanalyse

What does Ocular Therapeutix do?

Ocular Therapeutix Inc is a US biotechnology company founded in 2006 by Amarpreet Sawhney and Michael Goldstein. Its focus is on the development and commercialization of ocular therapeutics. Ocular Therapeutix's business model is based on the use of proprietary technologies such as the hydrogel platform (which involves the use of hydrophilic polymers to develop AMC-based therapeutics), the compounds embedded in the polymer matrix, and the bonding technology to develop new drug candidates. The company utilizes these technologies to develop and bring to market products that have the potential to meet clinical needs of patients. Ocular Therapeutix operates in two divisions - Retina and Severe Eye Diseases, and Dry Eye. The Retina and Severe Eye Diseases division focuses on the development of drugs for the treatment of retina diseases such as wet age-related macular degeneration, diabetic retinopathy, and macular edema. In this division, the company has developed DEXTENZA, which is used for the treatment of postoperative pain and inflammation after eye surgeries. DEXTENZA is a single-use implant that continuously releases medication and relieves inflammation. The Dry Eye division of Ocular Therapeutix focuses on the development and commercialization of drugs for the treatment of dry eye, a condition caused by inadequate tear production or quality. In this division, the company has developed ReSure Sealant - a hydrophilic bonding technology used to seal the eye surface during surgeries and injuries while maintaining eye moisture and preventing infections. Currently, the company is also developing DEXTENZA for the treatment of dry eye. The company is actively involved in research and development of new therapy options and has recently expanded its pipeline extensively. Ocular Therapeutix will soon expand to Europe and Asia and plans to market its products in various regions worldwide. Overall, Ocular Therapeutix has made significant progress in recent years by expanding its product range and advancing drug development. With a well-positioned pipeline and a growing business, the company is expected to achieve significant growth in the coming years. Ocular Therapeutix ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Ocular Therapeutix's P/E Ratio

The Price to Earnings (P/E) Ratio of Ocular Therapeutix is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Ocular Therapeutix's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Ocular Therapeutix is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Ocular Therapeutix’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Ocular Therapeutix stock

What is the price-to-earnings ratio of Ocular Therapeutix?

The price-earnings ratio of Ocular Therapeutix is currently -2.35.

How has the price-earnings ratio of Ocular Therapeutix changed compared to last year?

The price-to-earnings ratio of Ocular Therapeutix has increased by -62.99% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Ocular Therapeutix high compared to other companies?

Yes, the price-to-earnings ratio of Ocular Therapeutix is high compared to other companies.

How does an increase in the price-earnings ratio of Ocular Therapeutix affect the company?

An increase in the price-earnings ratio of Ocular Therapeutix would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Ocular Therapeutix affect the company?

A decrease in the price-earnings ratio of Ocular Therapeutix would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Ocular Therapeutix?

Some factors that influence the price-earnings ratio of Ocular Therapeutix are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Ocular Therapeutix pay?

Over the past 12 months, Ocular Therapeutix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ocular Therapeutix is expected to pay a dividend of 0 USD.

What is the dividend yield of Ocular Therapeutix?

The current dividend yield of Ocular Therapeutix is .

When does Ocular Therapeutix pay dividends?

Ocular Therapeutix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ocular Therapeutix?

Ocular Therapeutix paid dividends every year for the past 0 years.

What is the dividend of Ocular Therapeutix?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ocular Therapeutix located?

Ocular Therapeutix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ocular Therapeutix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ocular Therapeutix from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Ocular Therapeutix pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Ocular Therapeutix in the year 2023?

In the year 2023, Ocular Therapeutix distributed 0 USD as dividends.

In which currency does Ocular Therapeutix pay out the dividend?

The dividends of Ocular Therapeutix are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ocular Therapeutix stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ocular Therapeutix

Our stock analysis for Ocular Therapeutix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ocular Therapeutix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.